1. Copyright © 2002 American Medical Association. All rights reserved.
From: Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyA Losartan Intervention For Endpoint Reduction (LIFE) Substudy
JAMA. 2002;288(12): doi: /jama
Date of download: 11/8/2017
Copyright © 2002 American Medical Association. All rights reserved.

2. Copyright © 2002 American Medical Association. All rights reserved.
From: Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyA Losartan Intervention For Endpoint Reduction (LIFE) Substudy
JAMA. 2002;288(12): doi: /jama
Figure Legend:
CI indicates confidence interval.
Date of download: 11/8/2017
Copyright © 2002 American Medical Association. All rights reserved.

3. Copyright © 2002 American Medical Association. All rights reserved.
From: Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyA Losartan Intervention For Endpoint Reduction (LIFE) Substudy
JAMA. 2002;288(12): doi: /jama
Figure Legend:
CI indicates confidence interval. Percentage of patients with firstevent are shown for stroke and myocardial infarction.
Date of download: 11/8/2017
Copyright © 2002 American Medical Association. All rights reserved.

4. Copyright © 2002 American Medical Association. All rights reserved.
From: Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyA Losartan Intervention For Endpoint Reduction (LIFE) Substudy
JAMA. 2002;288(12): doi: /jama
Date of download: 11/8/2017
Copyright © 2002 American Medical Association. All rights reserved.

5. Copyright © 2002 American Medical Association. All rights reserved.
From: Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyA Losartan Intervention For Endpoint Reduction (LIFE) Substudy
JAMA. 2002;288(12): doi: /jama
Figure Legend:
*Titration upward encouraged if sitting systolic pressure was 140mm Hg or higher, but mandatory if it was 160 mm Hg or higher. Addition ofangiotensin-converting enzyme inhibitors, other angiotensin II AT1-antagonists,or other β-blockers prohibited.
Date of download: 11/8/2017
Copyright © 2002 American Medical Association. All rights reserved.